Jack Schim

848 total citations
19 papers, 472 citations indexed

About

Jack Schim is a scholar working on Psychiatry and Mental health, Pathology and Forensic Medicine and Physiology. According to data from OpenAlex, Jack Schim has authored 19 papers receiving a total of 472 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Psychiatry and Mental health, 10 papers in Pathology and Forensic Medicine and 8 papers in Physiology. Recurrent topics in Jack Schim's work include Migraine and Headache Studies (15 papers), Sympathectomy and Hyperhidrosis Treatments (7 papers) and Trigeminal Neuralgia and Treatments (7 papers). Jack Schim is often cited by papers focused on Migraine and Headache Studies (15 papers), Sympathectomy and Hyperhidrosis Treatments (7 papers) and Trigeminal Neuralgia and Treatments (7 papers). Jack Schim collaborates with scholars based in United States, Germany and Denmark. Jack Schim's co-authors include Andrew Blumenfeld, Thomas J. Chippendale, Jessica Ailani, Paul Stang, Steven D. Bender, Brad Klein, Avi Ashkenazi, Matthew S. Robbins, Deborah I. Friedman and Larry Charleston and has published in prestigious journals such as Neurology, Experimental Neurology and Headache The Journal of Head and Face Pain.

In The Last Decade

Jack Schim

18 papers receiving 446 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jack Schim United States 11 342 253 174 104 60 19 472
H-C Diener Germany 9 547 1.6× 385 1.5× 269 1.5× 80 0.8× 51 0.8× 9 696
Patrizia Ripa Italy 11 496 1.5× 254 1.0× 105 0.6× 138 1.3× 90 1.5× 16 606
Andreas Peikert Germany 8 364 1.1× 215 0.8× 198 1.1× 50 0.5× 51 0.8× 11 491
Aftab Alam United States 8 402 1.2× 226 0.9× 125 0.7× 43 0.4× 37 0.6× 12 459
Esma Dilli Canada 11 493 1.4× 281 1.1× 201 1.2× 59 0.6× 55 0.9× 21 567
Abbas Ghorbani Iran 13 253 0.7× 159 0.6× 83 0.5× 91 0.9× 46 0.8× 25 453
Ge Tan China 16 415 1.2× 198 0.8× 149 0.9× 48 0.5× 100 1.7× 33 586
Thomas N. Ward United States 13 409 1.2× 232 0.9× 142 0.8× 132 1.3× 45 0.8× 27 520
F. d’Onofrio Italy 13 256 0.7× 115 0.5× 69 0.4× 118 1.1× 38 0.6× 23 364
Nada Hindiyeh United States 10 466 1.4× 205 0.8× 175 1.0× 40 0.4× 100 1.7× 24 568

Countries citing papers authored by Jack Schim

Since Specialization
Citations

This map shows the geographic impact of Jack Schim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jack Schim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jack Schim more than expected).

Fields of papers citing papers by Jack Schim

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jack Schim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jack Schim. The network helps show where Jack Schim may publish in the future.

Co-authorship network of co-authors of Jack Schim

This figure shows the co-authorship network connecting the top 25 collaborators of Jack Schim. A scholar is included among the top collaborators of Jack Schim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jack Schim. Jack Schim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
2.
Cowan, Robert P., Michael J. Marmura, Hans‐Christoph Diener, et al.. (2022). Quantity changes in acute headache medication use among patients with chronic migraine treated with eptinezumab: subanalysis of the PROMISE-2 study. The Journal of Headache and Pain. 23(1). 115–115. 2 indexed citations
3.
4.
5.
Schim, Jack, Susan Hutchinson, Richard B. Lipton, et al.. (2021). Rimegepant is Safe and Tolerable for the Acute Treatment of Migraine in Patients Using Preventive Migraine Medications: Results from a Long-Term Open-Label Safety Study (2370). Neurology. 96(15_supplement). 4 indexed citations
6.
Grosberg, Brian M., et al.. (2021). Remote Electrical Neuromodulation for the Acute Treatment of Chronic Migraine (2007). Neurology. 96(15_supplement). 1 indexed citations
7.
Grosberg, Brian M., Liron Rabany, Tamar Lin, et al.. (2021). Safety and efficacy of remote electrical neuromodulation for the acute treatment of chronic migraine: an open-label study. PAIN Reports. 6(4). e966–e966. 20 indexed citations
8.
Faust, Elizabeth, Irina Pivneva, Keith A. Betts, et al.. (2021). Real-World Treatment Profiles, Clinical Outcomes, and Healthcare Resource Utilization of Patients with Migraine Prescribed Erenumab: A Multicenter Chart-Review Study of US Headache Centers. Neurology and Therapy. 10(1). 293–306. 22 indexed citations
9.
Blumenfeld, Andrew, Benjamin Frishberg, Jack Schim, et al.. (2021). Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: A Retrospective Chart Review. Pain and Therapy. 10(2). 809–826. 62 indexed citations
10.
Hutchinson, Susan, Jack Schim, Richard B. Lipton, et al.. (2021). Oral Rimegepant 75 mg is Safe and Well Tolerated in Adults With Migraine and Cardiovascular Risk Factors: Results of a Multicenter, Long-Term, Open-Label Safety Study (1995). Neurology. 96(15_supplement). 7 indexed citations
11.
Schim, Jack, Susan Hutchinson, Richard B. Lipton, et al.. (2020). Rimegepant 75 mg Demonstrates Safety and Tolerability Similar to Placebo With No Effects of Age, Sex, or Race in 3 Phase 3 Trials (1609). Neurology. 94(15_supplement). 1 indexed citations
12.
Loo, Li Shen, Jessica Ailani, Jack Schim, et al.. (2019). Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trials. The Journal of Headache and Pain. 20(1). 84–84. 30 indexed citations
13.
Blumenfeld, Andrew, Avi Ashkenazi, Uri Napchan, et al.. (2013). Expert Consensus Recommendations for the Performance of Peripheral Nerve Blocks for Headaches – A Narrative Review. Headache The Journal of Head and Face Pain. 53(3). 437–446. 143 indexed citations
14.
Blumenfeld, Andrew, et al.. (2010). Pure Tension-type Headache Versus Tension-type Headache in the Migraineur. Current Pain and Headache Reports. 14(6). 465–469. 11 indexed citations
15.
Blumenfeld, Andrew, Jack Schim, & Thomas J. Chippendale. (2007). Botulinum Toxin Type A and Divalproex Sodium for Prophylactic Treatment of Episodic or Chronic Migraine. Headache The Journal of Head and Face Pain. 48(2). 210–220. 64 indexed citations
16.
Schim, Jack & Paul Stang. (2004). Overview of Pain Management. Pain Practice. 4(s1). S4–18. 21 indexed citations
17.
Schim, Jack. (2003). Effect of preventive treatment with botulinum toxin type A on acute headache medication usage in migraine patients. Current Medical Research and Opinion. 20(1). 49–53. 10 indexed citations
18.
Lyden, Patrick, Michael Jacoby, Jack Schim, et al.. (2001). The Clomethiazole Acute Stroke Study in tissue-type plasminogen activator–treated stroke (CLASS-T). Neurology. 57(7). 1199–1205. 56 indexed citations
19.
Schim, Jack, Patrick D. Lyden, & Frank R. Sharp. (1981). Increased subcortical and laminar cortical 2-deoxy[14C]glucose uptake during cerebellar stimulation. Experimental Neurology. 74(2). 499–518. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by H-C Diener Breakdown of academic impact, for papers by Patrizia Ripa Breakdown of academic impact, for papers by Andreas Peikert Breakdown of academic impact, for papers by Aftab Alam Breakdown of academic impact, for papers by Esma Dilli Breakdown of academic impact, for papers by Abbas Ghorbani Breakdown of academic impact, for papers by Ge Tan Breakdown of academic impact, for papers by Thomas N. Ward Breakdown of academic impact, for papers by F. d’Onofrio Breakdown of academic impact, for papers by Nada Hindiyeh
Rankless by CCL
2026